Quality Considerations for Continuous Manufacturing of APIs

This poster discusses the draft guidance “Quality Considerations for Continuous Manufacturing” and provides information regarding FDA’s current thinking on the quality considerations for continuous manufacturing of small molecule drug substances.

FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.    

Phone - [phone] I [phone]